Antibody-targeted photodynamic therapy

Purpoe To ae the feaibility of conjugation of verteporfin (Viudyne, Parkedale Pharmaceutical, Rocheter, Minneota, UA) to antibody againt vacular endothelial growth factor. Deign Experimental tudy. Method Rabbit antimoue vacular endothelial growth factor polyclonal antibody wa conjugated to verteporfin. Fluorecence excitation-emiion pectra of verteporfin and conjugate were examined. Vacular endothelial growth factor-expreing murine endothelial cell were incubated with aline, verteporfin, or conjugate, followed by laer expoure or no laer expoure. Cell viability at 1 and 24 hour wa aeed via trypan blue excluion. Reult were analyzed by two-way analyi of variance with replication and the Bonferroni multiple comparion tet. Reult The fluorecence excitation-emiion pectrum of the conjugate wa imilar to that of verteporfin. After laer expoure, cell viability in conjugate-treated cell wa reduced to 6% at 1 hour (P < .0001) and to 4% at 24 hour (P < .0001), compared with approximately 40% in nonlaer-expoed, conjugate-treated cell. The cytotoxicity in the conjugate-treated cell wa higher than in verteporfin-treated cell expoed to laer, although the difference did not reach tatitical ignificance. Concluion The conjugation of verteporfin to polyclonal antibody i poible without the lo of it photoenitizing propertie. Conjugated verteporfin detroy cellular target at leat a effectively a verteporfin alone